The power of autoantibodies to enhance clinical development success in Systemic Sclerosis (SSc)

SSc is an autoimmune disease characterised by widespread vascular injury, progressive fibrosis of the skin and internal organs, and a specific pattern of autoantibodies. The clinical manifestations of SSc are highly heterogenous with significant internal organ manifestations causing a greater mortality rate than any other rheumatic disease. The diverse clinical spectrum and course of the disease poses a challenge for the development of novel targeted therapies for SSc. The identification of patient subgroups using autoantibody patterns can help to identify patients responding to a particular treatment.

NavigAID SSc has been developed using the ImmunoINSIGHTS SeroTag process: Oncimmune’s proprietary biomarker discovery engine. This diagnostic ‘magnifying glass’ helps in understanding the molecular basis of complex autoimmune diseases. NavigAID SSc is a well defined antigen panel that can define meaningful SSc disease subtypes and increase the probability of successful SSc therapy.